3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDIV
1
Study Type
Interventional
4
Observational
1
Sponsor
Cancer Type
Thoracic
1
Genitourinary
1
Gastrointestinal
1
Conditions
Melanoma
12
Carcinoma, Non-Small-Cell Lung
8
Neoplasms
4
Lung Neoplasms
4
Colorectal Neoplasms
2
Urinary Bladder Neoplasms
1
Recurrent Squamous Cell Lung Carcinoma
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Neoplasm Metastasis
1
Motor Activity
1
Kidney Neoplasms
1
Carcinoma, Renal Cell
1
Brain Neoplasms
1
Adenocarcinoma
1
Interventions
Blood Specimen Collection
6
Radiotherapy
2
Quality of Life
2
Phlebotomy
2
Interviews as Topic
2
Drug Therapy
2
zolbetuximab
1
trastuzumab deruxtecan
1
sargramostim
1
pembrolizumab
1
iopromide
1
capecitabine-irinotecan combination
1
X-Rays
1
Tumor Burden
1
Transurethral Resection of Prostate
1
Tomography, X-Ray Computed
1
Therapeutics
1
Surveys and Questionnaires
1
Risedronic Acid
1
Registries
1
Raloxifene Hydrochloride
1
Radiofrequency Ablation
1
Radiation, Ionizing
1
Radiation
1
Positron-Emission Tomography
1
Patient Reported Outcome Measures
1
Nivolumab
1
Molecular Diagnostic Techniques
1
Ipilimumab
1
Induction Chemotherapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Observational
×
Adenocarcinoma
×
Ipilimumab
×
Clear all
NCT03695835
2020-07-22
NIRPA
Gary Onik MD
Completed
27 enrolled